Basilard Bio Tech
Biotechnology, Southern, California, United States, 1-10 Employees
Phone Number: 81********
Who is BASILARD BIOTECH
We are Basilard BioTech. We have introduced our novel gene delivery technology platform, CellettoTM to transform the rapidly growing cell-based therapies market. CellettoTM is a different...
Read More
-
Headquarters: Southern California, California, United States
-
Date Founded: 2019
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from BASILARD BIOTECH
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Basilard BioTech
Answer: Basilard BioTech's headquarters are located at Southern, California, United States
Answer: Basilard BioTech's phone number is 81********
Answer: Basilard BioTech's official website is https://basilardbiotech.com
Answer: Basilard BioTech's revenue is Under $1 Million
Answer: Basilard BioTech's SIC: 8731
Answer: Basilard BioTech's NAICS: 541714
Answer: Basilard BioTech has 1-10 employees
Answer: Basilard BioTech is in Biotechnology
Answer: Basilard BioTech contact info: Phone number: 81******** Website: https://basilardbiotech.com
Answer: We are Basilard BioTech. We have introduced our novel gene delivery technology platform, CellettoTM to transform the rapidly growing cell-based therapies market. CellettoTM is a differentiated & superior solution for non-viral gene delivery. Cell and Gene Therapies (CGT) have immense potential to address unmet clinical needs by leveraging the power and diversity of cell functions. They offer the best hope for finding solutions to prevailing diseases that affect and kill millions of people. The main challenges now are improving upon the limitations of biological and ex-vivo gene delivery and scaling manufacturing (cost-effectively) to meet the needs of current/future cell therapies. This is the bottleneck CellettoTM addresses with our new, disruptive, IP-Protected mechanoporation solution that offers a better, mechanical (rather than biological), approach to gene delivery. In ex-vivo delivery, CellettoTM consistently achieves higher transfection and cell viability performance and yields vs. the industry leading bulk electroporation platform currently used widely. In viral delivery, CellettoTM provides greater scalability, safety, efficiency, & versatility than prevailing viral delivery methods, as well as lower cost & lead time. And CellettoTM is a superior platform for primary T cell engineering than both electroporation and the prevailing viral delivery methods.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month